查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954178

HER2陽性乳癌市場分析及預測（至2035年）：依類型、產品類型、服務、技術、組件、應用、最終用戶、模式、分期分類

HER2-Positive Breast Cancer Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 306 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計HER2陽性乳癌市場將從2024年的112億美元成長到2034年的142億美元，複合年成長率約為2.8%。 HER2陽性乳癌市場涵蓋針對HER2蛋白過度表現的治療方法，HER2蛋白過度表現會促進癌細胞增生。此類別包括單株抗體、蛋白酪氨酸激酶抑制劑和抗體藥物複合體。個人化醫療和標靶治療的進步正在推動市場擴張，滿足未被滿足的醫療需求並改善患者預後。盛行率的上升和生物技術的進步也為市場成長奠定了基礎。

HER2陽性乳癌市場正經歷蓬勃發展，這主要得益於標靶治療和個人化醫療的進步。單株抗體在治療領域佔據主導地位，在療效和患者預後方面展現出顯著優勢。蛋白酪氨酸激酶抑制劑緊隨其後，為第一線治療抗藥性的患者提供了極具前景的替代方案。診斷領域持續擴展，分子診斷和伴隨診斷在早期檢測和個人化治療中發揮關鍵作用。基因檢測和生物標記鑑定對於制定個人化治療策略至關重要。新興的生物相似藥展現出競爭優勢，並提高了治療方案的可近性和成本效益。臨床試驗和研究舉措不斷探索新的藥物組合和治療方法，持續推動創新。公眾意識的提高和早期診斷有助於提高生存率和患者生活品質。人工智慧在診斷和治療計畫中的應用可望透過最佳化治療效果和提升營運效率，進一步變革市場格局。

市場區隔
類型 單株抗體、蛋白酪氨酸激酶抑制劑、免疫療法、荷爾蒙療法、化療、標靶治療
產品 曲妥珠單抗、Pertuzumab單抗、Lapatinib、來那替尼、圖卡替尼、ado-曲妥珠單抗 emtansine、 Margetuximab、fam-曲妥珠單抗 deruxtecan-nxki
服務 診斷服務、治療服務、諮詢服務、後續觀察、臨床試驗和患者援助計劃
科技 次世代定序、生物標記檢測、伴隨診斷、液態生物檢體
成分 活性藥物成分、製劑及包裝
目的 醫院使用、診所使用、居家醫療、研究機構
最終用戶 醫院、癌症治療中心、研究機構、學術機構
給藥途徑 靜脈注射和口服給藥
步 早期、轉移期

HER2陽性乳癌市場正經歷市場佔有率、定價策略和新產品上市方面的動態變化。主要企業正專注於創新治療方法並推廣具有競爭力的定價模式。新型生物製藥和標靶治療的引入顯著改善了治療效果，推動了該市場的蓬勃發展。從區域來看，北美憑藉其先進的醫療基礎設施和有利的報銷政策，保持著領先地位；而新興市場則因醫療投資的增加而不斷擴大市場佔有率。競爭基準分析揭示了一個充滿活力的市場格局，各大製藥公司正透過策略聯盟和收購爭奪主導。監管的影響至關重要，嚴格的指導方針左右著藥物的核准和市場准入。美國食品藥物管理局管理局（FDA）和歐洲藥品管理局（EMA）不斷調整的政策，強調安全性和有效性，正在顯著影響市場動態。市場分析顯示，精準醫療正成為顯著趨勢，精準治療的發展動能強勁。生物相似藥的出現加劇了市場競爭，提供了更具成本效益的替代方案，並有助於提高患者的用藥可及性。在技​​術進步和意識提高的推動下，市場正處於成長軌道上。

主要趨勢和促進因素：

由於標靶治療和個人化醫療的進步，HER2陽性乳癌市場正經歷快速成長。關鍵趨勢包括新型HER2標靶治療的研發，有助於改善患者預後並拓展治療選擇。精準腫瘤學的整合使得有效的治療方法能夠根據個別患者的具體情況量身定做，從而提高療效並減少副作用。專注於聯合治療的臨床試驗也蓬勃發展。這些試驗旨在提高存活率，並為進行性或抗藥性乳癌患者帶來新的希望。此外，公眾意識的提高和早期診斷的普及正在擴大患者群體，從而推動對創新治療方法的需求。同時，製藥公司之間的策略聯盟和夥伴關係正在推動研發活動，並加速最先進治療的市場化。新興市場蘊藏著許多機遇，這些市場的醫療基礎設施正在發展，獲得先進治療的機會也不斷增加。能夠成功應對監管環境並提供具成本效益解決方案的公司將佔據有利地位，從而獲得可觀的市場佔有率。隨著研究不斷揭示 HER2 陽性乳癌的複雜性，預計市場將持續成長，為相關人員帶來光明前景。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 單株抗體
    • 蛋白酪氨酸激酶抑制劑
    • 免疫療法
    • 荷爾蒙療法
    • 化療
    • 標靶治療
  • 市場規模及預測：依產品分類
    • 曲妥珠單抗
    • Pertuzumab
    • Lapatinib
    • 奈拉替尼
    • 圖卡替尼
    • ado-曲妥珠單抗 emtansine
    • 瑪格妥昔單抗
    • Famtrastuzumab deruxtecan-nxki
  • 市場規模及預測：依服務分類
    • 診斷服務
    • 治療服務
    • 諮詢服務
    • 後續護理
    • 臨床試驗
    • 患者援助計劃
  • 市場規模及預測：依技術分類
    • 次世代定序
    • 生物標記檢測
    • 伴隨診斷
    • 液態生物檢體
  • 市場規模及預測：依組件分類
    • 原料藥
    • 配方
    • 包裝
  • 市場規模及預測：依應用領域分類
    • 醫院用途
    • 臨床應用
    • 居家醫療
    • 研究所
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 癌症治療中心
    • 研究所
    • 學術機構
  • 市場規模及預測：依管理途徑
    • 靜脈注射
    • 口服
  • 市場規模及預測：依疾病階段分類
    • 早期
    • 轉移期

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Macro Genics
  • Puma Biotechnology
  • Cytom X Therapeutics
  • Zymeworks
  • Pieris Pharmaceuticals
  • Immunomedics
  • Mersana Therapeutics
  • Molecular Partners
  • Sorrento Therapeutics
  • Oncobiologics
  • Alligator Bioscience
  • Astra Zeneca
  • Cure Vac
  • Glenmark Pharmaceuticals
  • Karyopharm Therapeutics
  • Mabion
  • Bicycle Therapeutics
  • Genmab
  • Bio NTech
  • Immuno Gen

第9章：關於我們

簡介目錄
Product Code: GIS26121

HER2-Positive Breast Cancer Market is anticipated to expand from $11.2 billion in 2024 to $14.2 billion by 2034, growing at a CAGR of approximately 2.8%. The HER2-Positive Breast Cancer Market encompasses treatments targeting the overexpression of the HER2 protein, which promotes cancer cell growth. This segment includes monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates. Advances in personalized medicine and targeted therapies are propelling market expansion, addressing unmet medical needs and improving patient outcomes. The market is poised for growth due to increasing prevalence and advancements in biotechnology.

The HER2-Positive Breast Cancer Market is experiencing dynamic growth, driven by advancements in targeted therapies and personalized medicine. The therapeutic segment takes precedence, with monoclonal antibodies leading in efficacy and patient outcomes. Tyrosine kinase inhibitors closely follow, offering promising alternatives for patients resistant to first-line treatments. The diagnostics segment is expanding, with molecular diagnostics and companion diagnostics playing pivotal roles in early detection and treatment personalization. Genetic testing and biomarker identification are becoming integral in tailoring treatment strategies. Emerging biosimilars present a competitive edge, enhancing accessibility and affordability of treatment options. Clinical trials and research initiatives continue to fuel innovation, with novel drug combinations and treatment regimens under exploration. Increasing awareness and early diagnosis are contributing to improved survival rates and patient quality of life. The integration of artificial intelligence in diagnostics and treatment planning is anticipated to further revolutionize the market, optimizing therapeutic outcomes and operational efficiency.

Market Segmentation
TypeMonoclonal Antibodies, Tyrosine Kinase Inhibitors, Immunotherapy, Hormonal Therapy, Chemotherapy, Targeted Therapy
ProductTrastuzumab, Pertuzumab, Lapatinib, Neratinib, Tucatinib, Ado-trastuzumab Emtansine, Margetuximab, Fam-trastuzumab Deruxtecan-nxki
ServicesDiagnostic Services, Treatment Services, Consultation Services, Follow-up Care, Clinical Trials, Patient Support Programs
TechnologyNext-Generation Sequencing, Biomarker Testing, Companion Diagnostics, Liquid Biopsy
ComponentActive Pharmaceutical Ingredients, Formulations, Packaging
ApplicationHospital Use, Clinic Use, Home Care, Research Institutes
End UserHospitals, Cancer Treatment Centers, Research Laboratories, Academic Institutions
ModeIntravenous, Oral
StageEarly Stage, Metastatic Stage

The HER2-Positive Breast Cancer Market is witnessing dynamic shifts in market share, pricing strategies, and new product launches. Key players are focusing on innovative therapies, driving competitive pricing models. The market is characterized by the introduction of novel biologics and targeted therapies, enhancing treatment efficacy. Geographically, North America maintains a dominant position due to advanced healthcare infrastructure and favorable reimbursement policies, while emerging markets are gaining traction with increased healthcare investments. Competition benchmarking reveals a robust landscape with major pharmaceutical companies vying for leadership through strategic collaborations and acquisitions. Regulatory influences are paramount, with stringent guidelines shaping drug approvals and market entry. The FDA and EMA's evolving policies significantly impact market dynamics, emphasizing safety and efficacy. Market analysis indicates a trend towards personalized medicine, with precision therapies gaining momentum. The competitive intensity is heightened by the entry of biosimilars, offering cost-effective alternatives and expanding patient accessibility. The market's trajectory is set for growth, driven by technological advancements and increased awareness.

Geographical Overview:

The HER2-Positive Breast Cancer Market is witnessing varied growth dynamics across different regions. North America leads, propelled by advanced healthcare infrastructure and substantial R&D investments. The presence of key pharmaceutical players and a high prevalence of breast cancer cases further bolster the market. Europe follows, driven by strong healthcare systems and government support for cancer research. The region's focus on innovative therapies and clinical trials enhances its market position. In Asia Pacific, the market is expanding rapidly due to rising awareness and improved healthcare access. Countries like China and India are emerging as significant growth pockets, supported by increasing healthcare expenditure and a large patient pool. Latin America and the Middle East & Africa are also showing promising potential. In Latin America, growing healthcare investments and awareness campaigns are driving market growth. Meanwhile, the Middle East & Africa are focusing on improving cancer care infrastructure, recognizing the importance of early diagnosis and treatment.

The HER2-Positive Breast Cancer Market is significantly influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea, with their robust pharmaceutical sectors, are navigating trade tensions by enhancing local research capabilities and forging strategic alliances to mitigate import dependencies. China, under export restrictions, is intensifying efforts to boost its biopharmaceutical innovation, aiming for self-reliance. Taiwan, while a critical player in medical technology, remains vulnerable to geopolitical tensions. Globally, the HER2-Positive Breast Cancer Market is poised for growth, driven by advancements in targeted therapies. By 2035, market evolution will hinge on collaborative innovation and resilient supply chains. Middle East conflicts, affecting global energy prices, could indirectly impact pharmaceutical manufacturing costs, influencing market dynamics and strategic planning.

Key Trends and Drivers:

The HER2-Positive Breast Cancer Market is experiencing rapid growth driven by advancements in targeted therapies and personalized medicine. Key trends include the development of novel HER2-targeted treatments, which are enhancing patient outcomes and expanding therapeutic options. The integration of precision oncology is allowing for more effective treatment regimens tailored to individual patient profiles, thereby improving efficacy and reducing adverse effects. The market is also witnessing a surge in clinical trials focusing on combination therapies. These trials aim to improve survival rates and offer new hope for patients with advanced or resistant forms of the disease. Furthermore, increased awareness and early diagnosis are contributing to a growing patient pool, thereby driving demand for innovative treatments. Additionally, strategic collaborations and partnerships among pharmaceutical companies are fostering research and development efforts. This is accelerating the introduction of cutting-edge therapies to the market. Opportunities abound in emerging markets where healthcare infrastructure is evolving, and access to advanced treatments is expanding. Companies that can navigate regulatory landscapes and offer cost-effective solutions are well-positioned to capture significant market share. As research continues to unravel the complexities of HER2-positive breast cancer, the market is poised for sustained growth, offering promising prospects for stakeholders.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Mode
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Tyrosine Kinase Inhibitors
    • 4.1.3 Immunotherapy
    • 4.1.4 Hormonal Therapy
    • 4.1.5 Chemotherapy
    • 4.1.6 Targeted Therapy
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Trastuzumab
    • 4.2.2 Pertuzumab
    • 4.2.3 Lapatinib
    • 4.2.4 Neratinib
    • 4.2.5 Tucatinib
    • 4.2.6 Ado-trastuzumab Emtansine
    • 4.2.7 Margetuximab
    • 4.2.8 Fam-trastuzumab Deruxtecan-nxki
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Diagnostic Services
    • 4.3.2 Treatment Services
    • 4.3.3 Consultation Services
    • 4.3.4 Follow-up Care
    • 4.3.5 Clinical Trials
    • 4.3.6 Patient Support Programs
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Biomarker Testing
    • 4.4.3 Companion Diagnostics
    • 4.4.4 Liquid Biopsy
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Active Pharmaceutical Ingredients
    • 4.5.2 Formulations
    • 4.5.3 Packaging
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Hospital Use
    • 4.6.2 Clinic Use
    • 4.6.3 Home Care
    • 4.6.4 Research Institutes
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Cancer Treatment Centers
    • 4.7.3 Research Laboratories
    • 4.7.4 Academic Institutions
  • 4.8 Market Size & Forecast by Mode (2020-2035)
    • 4.8.1 Intravenous
    • 4.8.2 Oral
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Early Stage
    • 4.9.2 Metastatic Stage

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Mode
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Mode
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Mode
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Mode
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Mode
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Mode
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Mode
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Mode
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Mode
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Mode
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Mode
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Mode
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Mode
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Mode
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Mode
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Mode
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Mode
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Mode
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Mode
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Mode
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Mode
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Mode
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Mode
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Mode
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Macro Genics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Puma Biotechnology
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Cytom X Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Zymeworks
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Pieris Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Immunomedics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Mersana Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Molecular Partners
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Sorrento Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Oncobiologics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Alligator Bioscience
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Astra Zeneca
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Cure Vac
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Glenmark Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Karyopharm Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Mabion
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Bicycle Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Genmab
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Bio NTech
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Immuno Gen
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us